Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe

BACKGROUND: First-line maintenance erlotinib in patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) has demonstrated significant overall survival and progression-free survival benefits compared with best supportive care plus placebo, irrespective of epidermal growth factor...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Walleser, Silke, Ray, Joshua, Bischoff, Helge, Vergnenègre, Alain, Rosery, Hubertus, Chouaid, Christos, Heigener, David, de Castro Carpeño, Javier, Tiseo, Marcello, Walzer, Stefan
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2012
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3447427/
https://ncbi.nlm.nih.gov/pubmed/23028234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S31794
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki